Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in upcoming investor conferences. The company will attend the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 4, 2024, and the 2024 Wells Fargo Healthcare Conference in Boston, MA on September 5, 2024.
During these events, Caribou's leadership team will engage in one-on-one meetings with registered investors. This presents an opportunity for the company to showcase its progress and discuss its innovative CRISPR genome-editing technology with potential investors. For those interested in more details about Caribou's participation, additional information can be found on the Events page of the company's website.
Caribou Biosciences (Nasdaq: CRBU), un'azienda biotecnologica leader nello stadio clinico di editing genomico CRISPR, ha annunciato la sua partecipazione a prossimi conferenze per investitori. L'azienda parteciperà alla 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley a New York, NY, il 4 settembre 2024, e alla Conferenza Sanitaria 2024 di Wells Fargo a Boston, MA, il 5 settembre 2024.
Durante questi eventi, il team dirigente di Caribou avrà incontri uno a uno con investitori registrati. Questa è un'opportunità per l'azienda di mostrare i suoi progressi e discutere della sua innovativa tecnologia di editing genomico CRISPR con investitori potenziali. Per coloro che sono interessati a ulteriori dettagli sulla partecipazione di Caribou, ulteriori informazioni possono essere trovate nella pagina Eventi del sito web dell'azienda.
Caribou Biosciences (Nasdaq: CRBU), una destacada empresa biofarmacéutica en etapa clínica de edición del genoma CRISPR, ha anunciado su participación en próximas conferencias para inversores. La empresa asistirá a la 22ª Conferencia Anual Global de Salud de Morgan Stanley en Nueva York, NY, el 4 de septiembre de 2024, y a la Conferencia de Salud 2024 de Wells Fargo en Boston, MA, el 5 de septiembre de 2024.
Durante estos eventos, el equipo directivo de Caribou llevará a cabo reuniones uno a uno con inversores registrados. Esta es una oportunidad para que la empresa muestre su progreso y discuta su innovadora tecnología de edición del genoma CRISPR con inversores potenciales. Para aquellos interesados en más detalles sobre la participación de Caribou, se pueden encontrar más información en la página de Eventos del sitio web de la empresa.
Caribou Biosciences (Nasdaq: CRBU)는 선도적인 임상 단계 CRISPR 유전자 편집 생명공학 회사로, 다가오는 투자자 회의에 참여할 것이라고 발표했습니다. 이 회사는 2024년 9월 4일 뉴욕(NY)에서 열리는 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스와 2024년 9월 5일 보스턴(MA)에서 열리는 웰스 파고 헬스케어 컨퍼런스에 참석할 예정입니다.
이 행사 동안 Caribou의 리더십 팀은 등록된 투자자들과의 1대1 회의를 진행할 것입니다. 이는 회사가 성과를 보여주고 잠재 투자자들과 혁신적인 CRISPR 유전자 편집 기술에 대해 논의할 수 있는 기회입니다. Caribou의 참여에 대한 추가 정보는 회사 웹사이트의 이벤트 페이지에서 확인할 수 있습니다.
Caribou Biosciences (Nasdaq: CRBU), une entreprise biopharmaceutique de premier plan dans la phase clinique d'édition du génome CRISPR, a annoncé sa participation à des conférences pour investisseurs à venir. L'entreprise assistera à la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley à New York, NY, le 4 septembre 2024, et à la Conférence Santé 2024 de Wells Fargo à Boston, MA, le 5 septembre 2024.
Lors de ces événements, l'équipe dirigeante de Caribou participera à des réunions individuelles avec des investisseurs enregistrés. Cela offre une opportunité à l'entreprise de présenter ses progrès et de discuter de sa technologie innovante d'édition du génome CRISPR avec des investisseurs potentiels. Pour ceux qui souhaitent obtenir plus de détails sur la participation de Caribou, des informations supplémentaires peuvent être trouvées sur la page Événements du site Web de l'entreprise.
Caribou Biosciences (Nasdaq: CRBU), ein führendes biopharmazeutisches Unternehmen in der klinischen Phase der CRISPR-Genom-Editierung, hat seine Teilnahme an bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird an der 22. Jahreskonferenz für globale Gesundheitsversorgung von Morgan Stanley in New York, NY, am 4. September 2024, und an der Wells Fargo Gesundheitskonferenz 2024 in Boston, MA, am 5. September 2024, teilnehmen.
Während dieser Veranstaltungen wird das Führungsteam von Caribou eins-zu-eins-Gespräche mit registrierten Investoren führen. Dies bietet dem Unternehmen die Gelegenheit, seine Fortschritte zu präsentieren und seine innovative CRISPR-Genom-Editierungstechnologie mit potenziellen Investoren zu besprechen. Für interessierte Personen, die mehr über die Teilnahme von Caribou erfahren möchten, sind weitere Informationen auf der Veranstaltungsseite der Unternehmenswebsite verfügbar.
- None.
- None.
BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company leadership will participate in the following event and investor conferences:
- Morgan Stanley 22nd Annual Global Healthcare Conference, New York, NY
September 4, 2024
- 2024 Wells Fargo Healthcare Conference, Boston, MA
September 5, 2024
During these conferences, Caribou leadership will conduct one-on-one meetings with investors registered. For more information, visit the Events page on Caribou’s website.
About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
FAQ
Which investor conferences will Caribou Biosciences (CRBU) attend in September 2024?
What type of meetings will Caribou Biosciences (CRBU) conduct at these conferences?
Where can investors find more information about Caribou Biosciences' (CRBU) participation in these events?
What is Caribou Biosciences' (CRBU) main focus as a company?
